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Accumulating evidence suggests that psoriasis may 
be a genetically deterlnined hnmunogenic, inflalD-
matory disorder based on an ongoing autoreactive 
Th-1 response. SystelDic imlDunosuppressive therapy 
is highly effective but fraught with longterm side 
effects . Our research therefore focuses on therapeutic 
strategies that induce local im.munosuppression in 
the skin by topical, transepiderlDal delivery of immu-
nosuppressive drugs. SDZ 281-240 is a newly devel-
oped macrolide of the ascomycin type . It is immuno-
suppressive by a mechnism of action similar to that of 
FK506 but has no antiproliferative activity against 
keratinocytes ill vitro. To evaluate whether SDZ 281 -
240 exhibits antipsoriatic activity when applied topi-
cally, we tested 15 patients with severe, recalcitrant 
psoriasis, using a nlicroplaque assay in a randomized, 
double-blind, placebo-controlled study, comparing 
A ccumulating evidence suggests that psoriasis is an immunogenic, autoreactive, inflammatory disorder based on an ongoing, chronic Th-l cell response (Baker and Fry, 1992; Schlaak e/ Il l , 1994; Uyemura et 111,1994). This concept is supported by the clinjca l 
observation that complete remjssion of psoriasis can be achieved by 
systemic immunosuppressive therapy employing cyclosporin A 
(CyA) (Ellis et 111, 1986) and FKS06 Oegasothy el 111, 1992). Since 
CyA is strikingly effective even in patients who have fol.iled other 
aggressive treatments, it is presently considered th e most important 
addition to the therapeutic armamentarium available for the severe 
forms of tlns common and sometimes disab ling disease (Griffiths e( 
aI, 1989; Mihatsch and Wolff, 1992). As is true for other effective 
systemic therapies, such as psoralen-photochemotherapy (Wolff 
and Honigsmann, 1981), methotrexate (Weinstein and McC u.l-
lough, 1976), retinoids (Ellis and Voorhees, 1987), or fumaric acid 
(Alttneyer e/ aI, 1994), there are concems about pote ntial side 
effects of longterm CyA use and it now appears that the ideal 
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mixed lym phocyte reaction. 
the therapeutic efficacy of the macrolide with a po-
tent halogenated corticosteroid and vehicle. All pa-
tients showed a significant inIprovement of psoriatic 
lesions treated with two concentrations of the mac-
rolide and, as expected, with the corticosteroid but 
not with placebo. Both concentrations of the macro-
lide led to clearing of psoriasis after 10 days of 
treatment and biopsies confirmed a reversal of the 
histopathological and immunopathological pheno-
type of psoriasis to that of normal skin. Thus, an 
hnmunosuppressive agent that interferes with early 
T cell activation can be designed to penetrate into 
psoriatic lesions when applied topically and to be 
functionally active within the skin to suppress the 
ongoing psoriatic process. Key words: topical i1ll"""'o-
sllppl'essive t1levapylasco1ll),cin. ] Invest Del'mato/ 106:701-
710, 1996 
approach to the control of pSOriaSIS would be loca l immune 
suppression by topica.lly applied drugs. The time honored use of 
potent halogenated corticosteroids, however, which are anti-in-
flammatory and immunosuppressive, leads to local and-if they are 
applied extensive ly-to systemic side efFects. Despite the £1ct that 
intralesio nal CyA induces remission of lesions (Baker el 111, 1989; 
Ho e( Ill, 1990) attempts to develop effective topical CyA treatment 
for psoriasis have been unsuccessful (Griffiths ellll , 1987). Recently, 
some of us reported on pharmacological studies in a pig model of 
allergic conta ct dermatitis indicating tllat immunosuppressive ma-
crolides may represent a novel class of topical agents for treatment 
of skin diseases (M eingassner and Sttitz, 1992). 
In tllis paper we report on the antipsoriatic effectiveness of a 
topically applied, novel macrolide of tile ascomycin type, which has 
been shown previously to display potent anti-inflammatory activ i-
ties in anima l models of a.llergic contact dermatiti s.' We show that 
a nonsteroida.lmolecule that inhibits T cell activation is functiona.lIy 
active within the tissue after topical application and leads to a 
reversal of the clinical, histopathological, and immunopathological 
phenotype of psoriasis to normal. 
PATIENTS AND METHODS 
Patients: 15 patients with severe recalcitrant plaque psoriasis who were 
otherwise hea lthy were included in the study. T heir ages ranged from 
I Meingassner J G , Baumann K, Grassberger M , Stutz A. TopicaJ activity 
of the immunosuppressive macrolide SDZ 281-240 in animal models of 
allergic contact dermatitis. J I,IIIesl Del1l1olo/102:599. 1994 (abstr.) 
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Figure 1. Structure of SDZ 281-240. 
30-65 )'r (mean 47 yt). with a duration of disease from 5-40 (mean :1 7) yr. 
All paticnts had previously received v;lriollS topical :md systemic therapeutic 
I·egimens including glucocorticosteroids, tar preparations, psoralcn-photo-
chclllorhcrapy, rcrinoids, or eyA. As a prerequisite for clHrancc into the 
study. the patients had to be off any topical or systemic an tipsoria tic 
treatn1cnt for 2 n10 and did not rece ive al1)' anti-illflaullllatocy o r antipro-
liferative systemic therapy for other conditions. In formed consent was 
obtained 'Illd the study protocol was approved by the Ethical Committee of 
the University of Vienna. 
Drugs T he newly developed macrolide SDZ 281-240 is an ascolllydn 
derivative \.vieh an anei- inRaIl11113tory);,nm uno5uppressivc action sirnil;:lr [0 
FKS06 (Fig 1). SDZ 281-240 binds ill IIitro to the macrophilin-binding 
protcin FI( BP-l2 thereby inhibiting the phosphatase activity o f calcine urin 
and prcventing the assembl y and activation oft"ll1scription f;,ctors NF-AT 
and NF-KB; it thus intcrferes with T cell activation (Gtassbergcr and 
Ba umann, 1993). SDZ 281-240 was eva luated topically in a double-blind, 
placebo-controlled withill-p:tticnt stud)' for its alltipsol·iatic activity using 
the microplaque assay as described below. It was employed at COllcelltra-
tions of 1 % and 0.1% in an oil! water-formulation and comparcd with 
placebo (vehicle) alld 0.05% c1obctasol-17-propionatc (CP) cream as posi-
tive contro l. 
Two-Way Murine Mixed Lymphocyte Reaction (MLR) Female. 
8-10 wk old CBA (H_ZK) and BALB/c mice (B _2") were obta ined from 
Life Technologics. Fullingsdorf, Switzerland. Singlc spleen cell suspensions 
wcre prepa.red by standard techniques and equal amounts of sp leen ce lls 
ohtained frolll the two mouse strains were mi xed. 2 X 105 ccll s per well 
(1 X 10' cell s from each strain) were incub:lccd with serial dilutions 
(0.05-100 nM) ofSDZ 28.1 - 24Q in 200 1-'1 serum-free CG-medilllll (l3iorcba. 
Base l. Switzerland) in fl:lt bottom tissue cul ture microtitCl" pl;!tes for 4 d at 
37°C in 5% CO (Meo, J 979; Strong eI ai, 1973). Eight 3-fold dilution stcps 
in duplicatcs pcr compound were pCrf0n11ed. O ne microcuric [31-1) thymi-
dine (2 C i/mm ol; Amersham . 13uckingbmmhire, UK) was added to eacb 
well. The p\;!tes werc subsequently incubatcd for an additional 16 h . Cells 
were harvested (Bctaplote 96-well harvester) on filter paper Filtermat A, 
wbich was tben washed. dricd. and coun ted "ftc r addition of scintilla tion 
liquid (Bcta Plate Seint) in a Betaplatc counter (entire equipment frol11 
Wallac Oy. Turku, Finland). T he proliferation of BALBlc cells "lone was 
taken as background value (low control) of the MLR and was subtractcd 
frol11 " II va lues. Proliferation of mixed cells without any compo und was 
taken ;I S 1.00% proliferation (hjgh concrol) . 
Keratinocyte Proliferation Assay HaCaT cel ls. sponraneously trans-
formed, nontumotigcnic IlUnwl1 kcratinocytcs (Boukamp eJ al. 1988; Wini-
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Table I. Antibodies Used in This Study 
Antibody Dilution Source Compan y 
CD3 
CD4 
CDS 
CO l a 
H1.A-DR 
1:400 
01 :25 
1:200 
1:1 000 
1:500 
Fi laggr;'l 1: I 000 
In volucrin 01:10 
Ki-67 I'llre 
CD25 (IL 2R) 01 :05 
ELAM (E-seleccin) 1:1000 
ICAM- 1 1:1000 
PECAM 1 :2000 
VCAM-l 1: 1000 
EN- 4 1:400 
BMA-120 1:100 
Mouse 
Monsc 
Mouse 
MOllse 
Mouse 
Dako 2600 Glastrup Denmark' 
Ort1>o Diagnostic Systems. NJ 
Dako 2600 Glastrup, Denmar~ 
Orrho Diagnostic Systems, NJ 
Becton-Dickinson. San J ose, 
CA , 9513 1, 1807 
MOllse Paescl + Lorei Frankfurt/M 
0-60596 Germany .. 
Rabbit Paesel + Lorci Frankfu rt/M 
D-60596 Gc rman y ., 
MOllse Dianova, Hamburg 1, D- 2000, 
Germany 
Mo use Inunllnotech. Marseille 13276 
Fr,1nce . 
MOllse I3ritish Biotechnology, Abing-
don, OX l43 YS , UK 
Mouse British Biotechnology, Abing-
don, OX 143 YS. UK 
Mouse British Biotecbnolog)'. Abing-
don. OX ·143 YS, UK 
MOllse !"l... + I Systems. Abingdon , 
OX 143, YS UK 
Mouse Sera lab, C rawley Down, Sus-
sex, 1<.1110 4FFUK 
Mouse Behring. D-20251 H amburg. 
Germany 
------------------------------~----------~, 
ski and Foster. t 992) were obtained from N . FlISClljg (Gcrman Cancc~ 
R.csearch Cenrer, Heidelberg. Germany) . The HaCaT cells were cul tivatcq 
in DM.EM + 5'1., fetal calf serUm and seeded into microt.iter plates at 400(1 
cclls/O.2 l111!wel.l. After 24 h the llIediullJ was replaced with fres h mediu]]\ 
contallllng SDZ 28 '1-240 in concentrations from ·1 to 1 DO /LM (in triplicate). 
After 3 further d"ys of incubation , ce ll mass rela tive to untreated con trol~ 
was measured by a sensitive co lorimetric assay for protein using sll lforho, 
dam;ne .B (Skehan el 01, 1990). IC sil ref"rs to the concentration needed co 
reach half of the maximal ce ll growth inhjbition. R esu lts reflect the averao,' 
and standard deviations of :It least two indcpendent experiments. " 
Study Design The microplaquc assay ell1p lo)'ed is based on tl,e applica_ 
tion of the test drug to circuI11scribcd test arC;IS within One o r lnarc larnc 
psoriatic plaques usin g Finn Chambers (1.8 Clll i" di 'IIlJ cter) allowing fo;" 
minimal distance of 2 cm bctwecn the test arcas. odcd preparations of 1 % 
SDZ 281-240, 0.1'X, SDZ 281 -240,0.050;', C P. and placebo were random\'· 
assigned to four test areas within thc psoriatic plaques to be tcsted and we~ 
app li ed within Finn C hambers after the plaque had bcen washed with water. 
Neither obse rver nor subjccts knew thc contents of the matcrials applied to 
the skin. and the codes labeling individual preparations varicd from patiel1C 
to patient. Fifty milligrams of the test preparations we I·e accomlllodated in 
each chamber, which corresponds to 0.5 mg 'lI1d 0.05 Illg of SDZ 281 -_40 
ill the I % and 0.1 % formulation, respectively. A sen,ioccl usive dressing 
W:lS "pplicd to tl,e cntire plaque and left in p lacc for 24 h . The dressing 
W<lS remo ved every 24 h and the codcd study medications wc re reapplied 
to their respecti ve test sitcs, the whole procedurc bcing repcated dRily for 
10 d. 
Figure 2. The novel macrolide produces clinical and histologiCal 
improvement and reduces Ki-67-staining kcratinoeytes. A psoriatic 
plaque is shown before (lI) and ou day 11 (6) after d"ily :lpplic:ltion of 1% 
SDZ 281-240 (test sice 2). O. I'X, SDZ 281-240 (test sitc 5), 'lIld placebo (rest 
site 3) using the micropI:.qll c assa)'. T her" is a pronounced (test site 5) and 
complete (test site 2) reversal of psoriasis to normal. \n contrast, placebo 
(test site 3) docs not show any effect. The clinica l f'ndings arc paralleled by 
histopatho logical changcs that show a presc rvation of the psori<lric phel1o~ 
type w ith acanthosis. p'lfakeratosis. papillomatosis, tortuous capilJaries. and 
a dense inflammatory infiltrate in the placebo-o:catcd test .lice (r). whereas 
macrolide-trc;ltcd psoriasis shows practically normal skin (d). Epider1l1al 
hyperproliferatio n charactelistic of psoriasis :I"d indicated by nUmerou 
1<.1-67 C kcratinoc)'tcs is not influenced by placcbo (t') whereas in fI1acroljdL~ 
treated skin the number ofKi- 67 ·c proliferating keratinocytcs is signit'camly 
red uced and positive cells arc restricted to the basal cell lay"r (f). Scale bar. 
1 cm = 1001-'111. 
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Figure 3. T h e novel macrolide significan tly 
improves pso r iatic eryt hema and infiltr a t io n 
and red uces Ki67 positive proliferating ke-
ratinocytes and epid ermal thickness . Scores 
of mean values of erythema (n) and infiltration (1)) 
of 10 patients as assessed visually and by pa lpation 
of the test sites: there is a statistically signjficant 
reduction of both, psoriatic erythema (a) and 
infiltration (b) following SDZ 281-240 treatment 
in both 1 %, and 0.1 'v., concentration and CP treat-
ment' when compared with placebo. Data repre-
sent mean ± SD; p < 0.01 ofSDZ and CP versus 
control. Statistical <lIl<11ysis ofKi-67+ keratinocytes 
per 0.25 mm 2 epjdennjs (c, left) shows a significaJlt 
reduction fo Howing nwcrolidc and CP treatment 
in comparison to placebo. T he rigl'( pa llel of d ia-
gram c shows a significant reduction of epidcnnal 
thickness after 10 days of treatment with SDZ C 
281-240 and c1obetasol in comparison to placebo. 
Data represen t mean ± SD. 
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Table II . Semiquantitative Assessment (Scoresa ) of 
Erythema and Infiltration of Test Sites Treated with SDZ 
281- 240, Clobetasol- 17-propionate, and Placebo 
T reatnlcnt 
SDZ SDZ 
Paranl cter 281-240 1 'X, 281-2400.1% C P Placebo 
Erythema 
mean 10.25 9.95 9.85 17 .70 
SD 3.31 1.99 4.27 4.37 
median 10.50 9.75 9.75 18.25 
Infiltra tion 
mean 9.45 8.90 7.90 16.45 
SD 2.58 2. 11 2. 70 4.44 
median 9.25 9.25 7.25 17.25 
" O n days 0 (be fo re first application). 2. 4. 6. 8, .10 (last appli catio n), and 1 ·1 
c rythcl"u<1 and infi ltratio n of rest sites were scored with 3 (no change). 2 (severe 
involvement), 1 (moderate in volvement), and 0 (complete clearing) and scores added. 
Eval u ations Test sites were evaluated every other day-after rcmoval of 
the dressing and thc washing procedu re and before reapplication of study 
medications-using cunical criteria for the evaluation of erythema and 
induration based on an arbi traril y chosen 0-3 scale, whereby 3 denoted no 
change, 2 moderate improvement, 1. marked improvement, and 0 complete 
clearing. Photographs of test sites were taken under iden tical condi tions on 
days 0, 7, and 11. 
Biopsies Four-millimeter punch biopsies were t.l ken under local anes-
thesia using 2% mcpivacain from the psoriatic plaqucs to be tested on day 0 
before the first appucation of study medications and from aU test sites of all 
15 patients on day 11 (1 d after the final application of medication) . Biopsies 
were processed by standard techniques (Rappersberger e/ ai, 1990), both for 
routine paraffin embedding and H &E staining and for immunohistochem-
istry performed on cryostat sec60ns. Five-micrometer cryostat sections 
were air dried and fixed in acetone at -20°C, and a three- step immuno-
peroxidase (ADS) technique was performed. The sections were preincu-
bated in 10% normal goat serum fo r 30 nun at room temperature, then 
incubated with the appropriately diluted p.-imary monoclonal antibody 
(Table I) , for 2 h at room tempera ture, fo llowed by a PBS wash for 60 min 
wid1 three cbanges of the buffer solu60n. Afterwards , dle sections were 
incubated with the biotinylated goat anti-mouse IgG , or in the case of 
anti-involucrin antibodies, with goat a.nti-rabbit .J gG for 2 b at room 
temperature . Sections were then treated with a peroxidase-conjugated 
avidin biotin complex for 1 h at room temperature according to the 
estabushed procedures employed in our laborato ri es (Rappersberger et ai, 
1990). Finally. sections were incubated in 3-amino-9-ethylcarbazole (Sig-
ma, Deisenhofcn, German)') for 5-10 min , then washcd, counterstained 
with aqueous helmltoxyIin , and mounted in Aquadex (Merck, Dannstadt, 
Germany). Histopathological and immunomorphological evaluations in-
cluded measurement of epidermal thickness and assessment of the prolifer-
ative activity ofkeratinocytes as expressed by the number of Ki -67-positive 
kera tinocytes per 0.25 mm 2 of epidermis, eva luation of the pattern of 
involucrin and fi laggrin expression as a measure of epidermal differentiation, 
and assessment o f the state of activation of keratinocytes by HLA-DR and 
ICAM -l labeling. In addition , the density and composition of the inAam-
matory infiltra te was assessed by evaluating the expression of the differen-
tiation markers CD3, CD4, C D8, ;1I1d CDl a ,lI1d the expression of CD25 
(lL-2 receptor alpha chain) and l or I-ILA-DR on inAammatory ce lls (Pet-
zelbauer c ( ai , 1991; Table I) . 
To identify endothelial cells of cap"illaries within the derma'! papi llae and 
to di ffe rentiate endotheLial ce lls from CD54 + (I CA M-1 +) leukocytes, seri al 
cryos tat scctions were also stained with the endothelia l cell-specific mono-
clonal antibody BMA-120. Expression of adhesion molecules ICAM-l 
(CD54), ELAM-1 /E-selectin, VCAM-l, and PECA M/CD31 by the dermal 
microvascular endothelial ce ll s was visualized by staining with appropriate 
monoclona l antibo di es and activation of vascu lar structures was eX3nlincd 
by staining for HLA-DR in serial sections (Petzelbauer ct ai, 1994·; Table I) . 
Statistics T he scores for erythema and infi ltra60n of da ys 0, 2, 4,6,8, 10, 
and 11 were added in groups and analyzed fo r normal distribution (David 
test) and homogeneity o f variances (Hartley test). The data (proven 
normal.! y distributed and homogeneous) were subjected to an anal ys is of 
va riance (repca ted measures) followed by the Dunett test. Quantitative 
analys is of the infi ltrating/ resting lymphocytes and keratinocytes was dOlle 
by co unting the number of CD3 ;' , CD4 +. CD8+, CD1 a + leukocytes, and 
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Ki-67 + keratinocytes per 0.25 mm2 of both epidernus and dermis in three 
different serial sections of each biopsy specimen. Counting was done 
indcpendendy by three investiga tors. The individual values obtained fo r 
each cell population in each patient were pooled and the mean number 
(mean :t SD) of leukocytes per square ullit (0.25 mn/ epidermis, 0.25 mm 2 
dermis, 0.5 mm2 epidermis and dermis) was detennined. Statistical analysis 
was performed using tile paired Student's t test. 
RESULTS 
Clinical Results A ll patients em'oll ed in the study showed a 
significant improvem ent of the test sites treated w ith the two 
concentrations of the ascomycin de riv ative and. as e,,:pected, with 
CPo Both the 1% and 0.1 % SDZ 281 - 240 preparations led to a 
r eduction of infiltration and erythema, which r esu lted in clearing 
of most test sites on d ay 11 (Figs Za, I" 3a). A pronounced reduc-
tion of the psoriatic erythema was observed within the first 4 d of 
trea tment and was follow ed b y a steady d ecline to almost complete 
b lanchi.ng on day 11 (Figs 2a,b, 3a) . Infiltration improved less 
dramatically during the initia l phase of topical treatm ent, but also 
resolved by d ay 11 (Figs 2a,ll, 3b). These clinical resuJts equaled 
those obtained and expected after the application of CP (Fig 3 a., b). 
a superpotent topical g lu cocorticosteroid . In contrast, placebo did 
not significantly a ffect e ither parame ter (Figs 2a,bj 3a,b). The 
clinical observations were confimled b y statistical anal yses of tile 
sum of scores. Et-ythema and infiltration of all test sites treated with 
1 % or 0.1 % SDZ 281-240 or CP differ ed significantly (p < 0.01) 
fi'om placebo- treated sites (Table II; Fig 3a,b) . 
Biological Profile of SDZ 281- 240 The two-way MLR using 
mouse spleen cells showed that SDZ 281 - 240 potently inhibited T 
cell activation. The ICso, which refers to the concentration n eeded 
to reach half of the maximal cell prolifera tion i.nJlibition as com-
pared with control, was 1.2 nM SDZ 281-240 (data not show n), 
indicating that SDZ 281 - 240 is inmlllnosuppressive if( Il itro and 
continning previous resuJts .:j: By contrast. a 10.000-fold higher con-
ceno'ation of SDZ 281-240 was required to inhibit the growth of tile 
human keratinocyte cell line H aCaT (ICso: 12 fLM. data not shown). 
indicating tllat its ptu'ely antiproliferative effect is negligible. 
Histopathology and Immnnomorphology The clinical find-
ings were paralleled b y histopathological changes (Fig 2c,d). SDZ 
281 - 240 treat.ment induce d an almost complete reversion ofpsori-
atic epidermal h yp e rplasia to normal within 10 d , at which time 
the re was no eviden ce ofpersisti..I1g parakeratosis. hy perkeratosis, or 
papillomatosis , and tlli s was true for both con centrations used. The 
inflammatol-Y infiltrate appeared marked ly reduced , and tortuouS 
vascular proliferations were hardly observed (Fig 2d). T hese 
features were q uite similar to those associa ted with CP treaOnent 
(data not shown). Placebo did not affect the histopatholog ical 
param e te rs of psoriasis such as parake ratosis, acandlOsis. and papillo-
matosis (Fig 2c). In addition, the density of the inflammatory infiltrate 
and capillary prolifera tions remained unalte red, and placebo- treated 
test sites th us retained their psoriatic phenotype (Fig 2c) . 
More specifical.ly. both concentrations of SDZ 281 - 240 red uced 
the th.ickness of hyperplastic psoria tic epidernlis as m easured in til e 
placebo-treated test site by a factor of 1.9 (i .e ., from 0,42 mm ± 
0.024 to 0 .22 mm ± 0.029; m ean ± SD), whereas CP therapy led 
to an even more pronounced decrease by a factor of 3.2 (i. e., from 
0.42 111m ::':: 0 .024 to 0.13 m111 ::':: 0.005; m ean ± SD) epidennal 
thickness (Fig 3c). SDZ 281-240 treatment also clearly reduced the 
number of prolife rating, i.e., Ki-67+ keratinocytes from a m ean of 
143 (± 52.9) prolife rating cells/0 .25 111111 2 epidermis to 29 cells (± 
15.2)/0.25 mm 2 epidermis (Figs 2eJ, 3c) . Proliferating kerati.llo-
cytes ofSDZ 281 - 240-treated psoriasis were mostly restricted to the 
basal cell layer in contrast to p lacebo-treated sites, where they 
occupied multiple suprabasa.I laye rs (Fig Ze,j) . A similar reduction 
of the proliferating cells was induced b y CP therapy but not placebo 
(Fig 3c) . 
Epidermal diffe rentiation as assessed by involucrin (Fig 4a, ") and 
fila ggrin (Fig 4c,d) sta.ining patterns also reverted to normal with 
both concentrations of SDZ 281 - 240 and CP treatment. Whereas 
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Figure 4a-d. The novel luacrolide has an effect on epidermal differentiation. Involuerin expression is seen throughout aU metabolica lly active 
la yers of the psoriatic epidennis under placebo treatmcnt (a), but is restricted to the upper sp inous and gra nular cell layers after 10 days of topical appli cation 
of the novel macrolide. showing a distribution pattern similar to that of normal hUlllan skin (II). There is a similar e tlcct of SDZ 281-240 nn filaggrin 
express ion that is found both in the spinous and gra nular cell la yers in placebo treated skin (c) but is expressed exclusively within the granular cel.l laye r after 
topica l application of the macro lide (d) . Scale bill', 1 em = 50 J.l.1ll. 
placebo did not a lter the disturbed express ion of filaggrin and 
involu crin within the epidermis, i.e., distribution within the entire 
spinous and occasion ally in the basal laye rs , SDZ 281-240 (Figs 
4a-d) , and CP (not shown) treatment reduced the expression of 
these two proteins to the granular and upper spinous cell layer, 
charactet; stic of normal skin (BerneI'd e( aI, 1992; Vall at el aI, 1994). 
Also, keratinocyte activation as exp ressed by focal stain ing for 
[-!LA-DR and lCA M-1, still present in placebo-treated psoriatic 
s~n , was abolished by SDZ 281-240 treatment (Fig 7a-d). 
SDZ 281-240 as well as CP had clear effects 011 the cellular 
infiltrate of the test sites (Fig 5a.-)). The inflammatory infiltrate in 
psorias is, predominantly consisting of CD3 + , activated HLA-DR + 
T lymphocytes . was sti ll evident in the placebo-treated test sites at 
the termination of the study. By contrast, after 10 d ofSDZ 281-240 
treatment, a reduction of CD3 + , CD4 + , and CD8 + intraepidennal 
and delmal lymphocytes was observed (Fig 5a-j). Although the 
decrease in intraepidermal CD3 + , CD8+ lymphocytes was statistically 
sign.ificant, the reduction of CD4 + lymphocyte counts was not (Fig 
Figure Sa-j. The novel macrolide depletes the psoriatic plaque of passenger leukocytes and restores epidermal Langerhans cell population. 
After 10 d of placebo treatment there is still a dense inAammatory infiltrate that is composed ofCD3 + (a), CD4 + (c), CDS + (c), and CD2S + (~) leukocytes. 
SDZ 281-240 topically applied for 10 d lc"ds to an almost complete dcpletion ofCD3 + (II), CD4+ (eI), CDS+ (f), and CD25 + (It) leukocytes from the psoriatic 
plaque. Also. psoriatic epidermis as shown ill the placebo- treated site (i) is repopulated with CDl a;- Langerhans cell s ()) when treated with the novel 
macrolide. Swlc /Jar , '1 cm = 100 J.l.nL 
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6a) ; if, however, lymphocyte counts within the epidenn is and dennis 
were added, sta tistical significance was obtained for the reduction of 
bo th CD3 + and CD4 + cells (Fig 6b, c). Furthemlore, there was a clear 
reduction of the number of CD25 + leukocytes after treatment with 
SDZ 281-240 (Fig 7g,II) . In addition, we observed a significam 
increase of CD1.a + Langerhans cells in the SDZ 281.- 240- treated sites 
(Fig SiJ, 6a- c). Since Lan gerhans cells are CD4 + , their increase may 
account fo r the statistically nonsignifican t reduction of the C D 4 + cell 
population within the epidermis of the clearing psoriatic plaque. CP 
therapy led to ,tl1 even more pronouJlced depletion of T cell subsets 
from the epidemlis and dennis (Fig 6a- c). 
Involution of psoriasis in the SDZ 281 - 240 and C P-trea ted bur 
not in placebo-trea ted sites was also evident in th e dermal micro-
vasculature. Stainin g for HLA- D R , ICAM - I , ELA M-l /E-selectin, 
PECAM /CD31, and VCAM-1, m olecules that are upregulated in 
psoriatic les ions (Pe tzelbauer el ti l , 1991), showed a pronowlced 
reduction o f these activation and adhesion/ endothdial transmigra-
tion p ro te ins in th e papillary capill aries and, to a lesser degree, also 
in the subpapiUary vascular pl exus in the SDZ 281 - 240 and CP bur 
n o t the pl acebo-trea ted sites (Fig 7a-j) . In addi tion, SD Z 281- 240 
therapy led to a redu ction o f endotheUal cells within the tips of the 
papillae as dem o nstra ted by labeUng with BMA-1 20, indicating a 
true regression of capillary prolife ration (Fig 7g,II) . 
DISC U SS IO N 
T he most poten t agents available fo r the topical trea tment of 
p soriasis are halogenated corticostero ids. In this study, we show 
that remission of plaque psoriasis can also be induced by the topical 
applica tion of a novel semis)'11thetic de rivative of the immunosup -
pressant m acroUde ascom ycin within a time span of 11 d as assessed 
by clinical , histopathological, and immunom orphological cri teria , 
thus con fi rming previously presen ted preliminary results2 . SDZ 
281-240 is immunosuppressive but no t antip ro life rative ill "il,.o; it 
in terferes with early T ce ll ac ti va tion and exhibits pronounced 
anti-inflammatory activities in anim al m odels of all ergic contact 
derm atiti s.:j: Like FK 506, this m:lcrolide inhibits an tigen-induced T 
cell activation by blocking ca lcium-dependent intrace llular signal-
ing, ul timately leading to a suppression o f the tran scription of early 
lymphokines, such as IL- 2, by binding to the common cytosolic 
recep tor m acrophilin (Grassberger and Ba umann, 1993) . We thus 
show that an immunosuppress ive agen t th at inte rferes wi th early T 
cell activa tion can be design ed to penetrate in to p soria tic lesions 
w hen applied topically and ca n be function ally active within lesions 
suppressing the psoriatic process . 
T hat psoriasis is mediated by immune mechanisms is suggested 
by its HLA association (B1 3, B1 7, C w6, D R7) (Elder el aI, 1994) , 
by an increased antigen-presenting cell activity and acti vated T cells 
within lesions that show a T h-1 cytokine pattern with lesional 
elevation of y-interferon and y-in terfe ron-inducible adhesion mol-
ecules (Baadsgaard el aI, 1989; Baker el til , 199 1; Baker and Fry; 
1992, Gearing el aI, 1990; Gottlieb el ai , 1986; U yemura el ai , 1993). 
and by being triggered by streptococci o r HIV (Kruger and D uvic, 
1994) . Immunological mechanisms in psoriasis are further sug-
gested by the improvement of this disease, not only by antiprolif-
erative/immunosuppressive drugs such as meth o trexate, but also by 
truly immunosuppressive compounds such as CyA, FK506, anti-
2 R appersberger K, Meingassner ] G, Fodinger D et aI. Clearing of 
psoriasis by a novel macrolide. J 1'/llesl De,.,,,alol 1.02:552, 1994 (abstr.) 
Figure 6. SDZ 281-240 induced changes of the inflammatory infil-
trate arc statistically significant. Statistical analysis of the composition 
of the inAammatory infiltra te of CD3 +, CD4 +, CDS +, and CDla~ 
leukocytes revea ls a significant reduction of CD3 '" and CDS+ passenger I 
leukocytes from epidermis (a) and dermis (b) . CD4 + ce ll depletion i 
significant if counts of epidennis (a) and dermis (/I) are taken together (e). 
Repopulation of the epidennis of the healing pSOliatic plaque with CDl a + 
Langerhans cells is also significant (a). Similar resul ts were obtained with CP 
(a- c) and 0.1'Yo SDZ 281-240 (data not shown) . Error bars define mean ::t: SD. 
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Figure 7a-h. SDZ 281-240 normalizes the expression of activation-, adhesion-, and trans!Digration !Darkers. The nonnal macrolide reduces 
the expression of HLA-DR. by ep idemlal keratinocytes. leukocytes, and endothelial ceils and downregulates the expression of adhesion and transmigration 
molecules on the papillary vascular plexus. HLA-DR. (a), lCA M-1 (e), and PECAM (e) expression in placebo-treated psoriatic skin are c1ead)' downregulated 
after macrolide treatment b) HLA-DR.; d) ICAM-1;j) PECA M) . Tlus downregulation is paralleled by a regression of papillary blood vessels as indicated by 
staining with BMA 120 (~. placebo; ii , macro lide treated sites). Scale bal'. 1 em = 100 f.1.111. 
CD3 and anti-CD4 monoclonal antibodies (Morel et aI, 1992 ; 
Nicolas et aI, 1991; Prinz et aI, 1991; Weinshenker et aI, 1989; 
Wong et aI, 1993) , and lymphocyte- selective to,uns (Gottlieb et aI, 
1995) and is further suggested by the acquisition or disappearance 
of psoriasis after bone marrow transplantation depending upon 
w hether donor or recipient has psoriasis (Eedy el aI, 1990; Gardem-
bas-Pain et aI, 1990). Studies of the cell ular infiltrate and cytokine 
patterns within psoriatic lesions strongly indicate a chronic T 
cell-mediated process involving the Th-l subset population 
(Schlaak et aI, 1994; Uyell1ura c/ ai, 1993). The association of 
activated IL- 2R + proliferating T cells in apposition to APCs 
suggests presentation of the T cell receptor with a putative foreign 
or self antigen by these cells, and it is speculated that activated T 
cells release y-interferon, which together with TNFa promotes 
rCAM-1 expression on keratinocytes to which T cells, attracted to 
the e p idermis by mediators and cytokines and arrested by activated 
endothelial cells, adhere via T cell LFA-l/keratinocyte rCAM-l 
interactions (Griffiths, 1994; Wakita and Takigawa, 1994). Cloning 
ofT cells from psoriatic lesions further suggests that these activated 
T cells produce as yet uncharacterized Iymphoki.n e(s) (Strange el aI, 
1993) to stimulate keratinocyte hyperproliferation, which results in 
the epidermal hyperplasia characteristic of this disease. 
In tlus study, we show that topical application of SDZ 281 - 240 
abolishes the psoriatic phenotype, leading to clinically normal skin 
within 11 d (Fig 2a,b), and that this is accompanied by a reversion 
of the psoriatic lustoJogy to normal. In addition, ehe proliferative 
activity of keratinocytes (as assessed by the n;Ab IG-67) is down-
regulated, and the expression and distribution pattem of epidermal 
maturation/ dilferentiation m arkers are normalized . More impor-
tantly , however, immunophenotyping revealed a significant reduc-
tion ofCD3 +, CD4 +, and CD8 + T cells , and more specifically, of 
HLA-DR + and IL- 2R + T cells from both epidemlis and dermis, an 
710 RAPPERSI1ER GER ET AL 
abolition ofHLA-DR, lCAM-t expression by keratinocytes, and a 
reversal of the CD1a -I- Langerhans cell number and distribution to 
normal. This and the reduction , although not complete abolition , 
ofHLA-DR, [CAM-t, VCAM-1, ELAM-l , and PECAM expres-
sion o n papillary vessels is simila r, albeit quantitatively not identi-
cal, to w hat occurs during systemic CyA treatment of psoriasis 
(Gottlieb e/ "I, 1992; G upta ct ai, 1989) and intra lesional injection of 
CyA into psoriatic lesions (Baker el ai , 1989; I-Io et ai, 1990) . Data 
indicating that our compound inte rferes w ith ea rly T cell activation 
and is not antiprolifera tive i/l " ill"O lead us to believe th at the 
reduction of epidermal prolife ration observed in this study may not 
be a direct effect of the drug on keratinocytes but may resu lt from 
a downregulation of T ce ll activation and consequent cytokine 
release. T hus, a mode of action ofSDZ 281-240 could be envisaged 
in which the compound downregulates activated T cells and, as the 
T cell-triggered and cytokine-mediated proliferation of keratino-
cytes subsides, the epiderrnis is allowed to revert to a no rmal state 
of proliferation and differentiation. T his would be in line with the 
recent observation that a system ically app lied lymphocyte- selective 
toxin (DAB389 IL-2) induced remission of psoriatic les ions, indi-
ca ting that psoriatic features are primarily linked to skin infiltrating 
IL-2 receptor-positive (CD2S -!- ) leukocytes (Gottlieb el a/, 1995) . 
At this time we do not know how long the beneficial effect 
observed for SDZ 281 - 240 lasts and whether prolonged treatment 
will induce tachyphylax is. Also, there are no experimental data on 
potential system ic immunosuppressive effects of transcutaneous 
SDZ 281 - 240 delivery. Although these appear unlikely from a 
quantitative viewpoint, this issue will have to be addressed in 
forma l clinical studies . Data available so fa r have not revea led 
in~i tative or contact sensitizing potentials of the compound. We do 
acknowledge that the resu lts shown occurred under a special type 
of occlusion and may thus not be as dramatic in a clinical setting, 
and therefore on ly clinical trials employing large area or whole 
body treatment wi ll eventually determine the role this or related 
compounds will play in the treatmen t of psoriasis. 
This st llri)' I/las pe,!orlllcd 011 the basis of a research coopcrnt;oll comracl belweell tlte 
Dcparl", elll oj Der",alolog)', Ullillersil), ~r Viel1lln, alld Ihe Salldoz Research 
IlIsl illlle, Viel1lln, fi "a"cen by a grallr prol,hlcll b), Ihe Sa llnoz COlllpall)" Basel, 10 
sllpporl research projecls ~r 1I111111n1 illlen'silo IJOlh illSlilllliolls. I~/e arc illneblen 10 C. 
Zellke (Preclillical R,~semdl , Salldoz Pllnnlla Lin., Basel, Swilzer/alld) mul AlllolI), 
I~/illis ki (Sa lldoz R esearch /lI slilllle, Viel1lln, A uSlria) Jorpe(fOrlllallc,' 'iflhe MLR 
alln kerar;'/OC)'le prolijerali,,,, assays. 
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